Annual General Meeting and Board Changes

RNS Number : 0207G
Oxford Biomedica PLC
05 May 2011
 

 

 

 

FOR IMMEDIATE RELEASE

5 May 2011

 

OXFORD BIOMEDICA PLC

ANNUAL GENERAL MEETING AND BOARD CHANGES

Oxford, UK - 5 May 2011: Oxford BioMedica (LSE: OXB), a leading gene therapy company, announced today that all resolutions proposed were duly passed at its Annual General Meeting (AGM), held today in London.

 

In accordance with Listing Rule 9.6.18, the following resolutions are those which were passed at the meeting concerning special business:

 

·     Resolution 6: to empower the Directors to allot equity securities, pursuant to section 551 of the 
Companies Act 2006 (the "Act"), up to an aggregate nominal amount of £3,149,585 with a further aggregate nominal amount of £3,149,585 authorised in connection with a rights issue, or where applicable, other proportionate offer;

 

·     Resolution 7: to empower the Directors to allot equity securities for cash, pursuant to section 
570 of the Act as if section 561 of the Act did not apply to such allotment, up to an aggregate nominal amount representing 5 per cent of presently issued shares;

 

·     Resolution 8: to extend the Oxford BioMedica plc Share Option Scheme on its current terms for five years from 1 February 2012.

 

·     Resolution 9: to extend the Oxford BioMedica plc Long Term Incentive Plan on its current terms for five years from 1 February 2012.

 

·     Resolution 10: to permit the Company to convene general meetings (other than annual general meetings) by not less than 14 days notice.

 

The full text of all the resolutions can be viewed in the Notice of Meeting by visiting our website at www.oxfordbiomedica.co.uk

 

Certified copies of the document setting out the above resolutions passed at the 2011 AGM have been submitted to the National Storage Mechanism and will shortly be available for inspection at: www.Hemscott.com/nsm.do.

 

The results of the proxy voting in advance of the meeting are shown below. On the Record Date (03 May 2011) there were 944,875,557 1p ordinary shares in issue, each carrying one vote per share.

 




 

 

 

Resolution

 

Votes 

For

Votes at 

Chairman's

Discretion

Votes at 

other proxy

Discretion

 

 Votes

Against

 

Votes 

Withheld

 

Total

votes cast

Result









Ordinary resolutions






1

366,724,525

286,462

1,792,205

183,015

10,529

368,996,736

Passed









2

365,388,618

293,062

1,792,205

414,743

1,108,108

368,996,736

Passed









3

366,724,408

286,801

1,792,205

157,081

36,241

368,996,736

Passed









4

366,736,464

288,111

1,792,205

153,492

26,464

368,996,736

Passed









5

366,658,614

293,401

1,792,205

230,670

21,846

368,996,736

Passed









6

365,267,950

286,801

1,792,205

366,397

1,283,383

368,996,736

Passed









8

351,435,346

290,183

1,792,205

349,446

15,129,556

368,996,736

Passed









9

366,415,760

290,183

1,792,205

377,604

120,984

368,996,736

Passed









Special resolutions






7

366,346,547

278,363

1,792,205

494,941

84,680

368,996,736

Passed









10

364,696,687

287,818

1,792,205

2,200,628

19,398

368,996,736

Passed









 

As announced on 21 March 2011, at the AGM the Chairman, Dr Alan Kingsman, left the Board of Oxford BioMedica. Nick Rodgers, previously Non-Executive Director, Senior Independent Director and Deputy Chairman, has become Chairman.

 

In addition to these changes, Dr Andrew Heath, Non-Executive Director, will now become the Senior Independent Director and Deputy Chairman.  

 

-Ends-

 

 

 

For further information, please contact:


Oxford BioMedica plc:

Lara Mott, Head of Corporate Communications

 

Tel: +44 (0)1865 783 000

 

Media/Financial Enquiries:

Katja Toon/Emma Thompson/Amber Bielecka

M:Communications

 

Tel: +44 (0)20 7920 2342

 

 

Notes to editors

1. Oxford BioMedica®

Oxford BioMedica plc (LSE: OXB) is a biopharmaceutical company developing innovative gene-based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs. The Company's technology platform includes a highly efficient LentiVector® gene delivery system, which has specific advantages for targeting diseases of the central nervous system and the eye; and a unique tumour antigen (5T4), which is an ideal target for anti-cancer therapy. Through in-house and collaborative research, Oxford BioMedica has a broad pipeline and its partners include sanofi-aventis, Sigma-Aldrich and Pfizer.  Further information is available at www.oxfordbiomedica.co.uk.

 


This information is provided by RNS
The company news service from the London Stock Exchange
 

END

 
 

RAGAAMBTMBAMBTB